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Abstract
Background:  Because a large proportion of patients with panic attacks receiving approved
pharmacotherapy do not respond or respond poorly to medication, it is important to identify
additional therapeutic strategies for the management of panic symptoms. This article describes a
randomized, rater-blind study comparing low-dose risperidone to standard-of-care paroxetine for
the treatment of panic attacks.
Methods: Fifty six subjects with a history of panic attacks were randomized to receive either
risperidone or paroxetine. The subjects were then followed for eight weeks. Outcome measures
included the Panic Disorder Severity Scale (PDSS), the Hamilton Anxiety Scale (Ham-A), the
Hamilton Depression Rating Scale (Ham-D), the Sheehan Panic Anxiety Scale-Patient (SPAS-P), and
the Clinical Global Impression scale (CGI).
Results: All subjects demonstrated a reduction in both the frequency and severity of panic attacks
regardless of treatment received. Statistically significant improvements in rating scale scores for
both groups were identified for the PDSS, the Ham-A, the Ham-D, and the CGI. There was no
difference between treatment groups in the improvement in scores on the measures PDSS, Ham-
A, Ham-D, and CGI. Post hoc tests suggest that subjects receiving risperidone may have a quicker
clinical response than subjects receiving paroxetine.
Conclusion: We can identify no difference in the efficacy of paroxetine and low-dose risperidone
in the treatment of panic attacks. Low-dose risperidone appears to be tolerated equally well as
paroxetine. Low-dose risperidone may be an effective treatment for anxiety disorders in which
panic attacks are a significant component.
Trial Registration: ClinicalTrials.gov Identifier: NCT100457106
Background
As described in the DSM-IV, panic attacks are discrete, par-
oxysmal episodes of intense fear and discomfort accom-
panied by both somatic and cognitive symptoms, which
occur in the absence of actual physical danger [1]. Panic
attacks are known to occur in a variety of psychiatric and
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medical disorders [2], and effective treatment for panic
symptoms is important for a large number of patients.
Research on the neurobiology of panic has demonstrated
a role for both serotonergic and noradrenergic neurotrans-
mitter systems [3-5]. Selective serotonin reuptake-inhibi-
tors (SSRIs) are currently the most widely used and
effective pharmacologic agents in the treatment of panic
attacks [6,7]. Currently, the U.S. Food and Drug Adminis-
tration has approved the use of fluoxetine, paroxetine,
and sertaline for the treatment of panic disorder [8]. The
utility and effectiveness of paroxetine for treating panic
disorder and relieving panic attacks has been shown in
multiple randomized and controlled trials [9-15]. Addi-
tionally, tricyclic antidepressants, monoamine oxidase
inhibitors, benzodiazepines, and anti-convulsants have
all been used in the treatment of panic disorders with var-
ying and generally reduced degrees of success [16-18].
Despite a multitude of available treatment options, a sub-
stantial fraction of patients with panic symptoms do not
respond or respond poorly to medication. Between 50
and 80% of patient with panic disorders receiving
approved pharmacotherapy continue to have panic
attacks and/or avoidance symptoms [12,19,20]. Another
study concluded that between 25 – 50% of patients will
experience a relapse of symptoms while receiving medica-
tion [21]. Thus, it is important to identify additional ther-
apeutic strategies for the management of panic.
Risperidone was approved by the FDA for treatment of
psychosis and schizophrenia in 1993. Risperidone has
receptor blocking activity at both the D2 receptor family
and serotonin receptors, and was therefore considered a
theoretical anxiolytic agent. Since then, risperidone has
been shown to have anxiolytic effects in patients with
schizophrenia and schizoaffective disorder [22,23]. Addi-
tionally, risperidone has been shown to be effective in the
treatment of anxiety arising in a variety of clinical settings:
depression with comorbid anxiety [24,25], treatment
resistant anxiety in the elderly [26], generalized anxiety
disorder [27], obsessive-compulsive disorder [28-31], and
post-traumatic stress disorder [32-35]. Many of these
studies reported the anxiolytic effect of risperidone
occurred at substantially lower doses than those used in
the treatment of psychosis, with a concomitant reduction
in the incidence of adverse effects [32,27,25].
Based on these positive findings and the results of our
own preliminary study [25], we felt that a trial of risperi-
done for the treatment of panic attacks was warranted. We
describe herein an exploratory, randomized, single-blind
trial of risperidone versus paroxetine for the treatment of
panic attacks. We hypothesized that risperidone will be as
effective as paroxetine in relieving panic symptoms.
Because of the low dose of risperidone used in this study,
we further hypothesized that risperidone would be better
tolerated than paroxetine. To our knowledge, this is the
first report of the use of risperidone as monotherapy in
the treatment of panic symptoms.
Methods
This randomized, rater-blinded, medication-controlled
study was reviewed and approved by the Beth Israel Med-
ical Center Institutional Review Board, and all subjects
provided written, informed consent to participate. The
study is publicly registered at ClinicalTrials.gov (Identi-
fier: NCT100457106) http://clinicaltrials.gov/ct2/show/
NCT00457106.
Subjects
The study subjects were recruited from the inpatient psy-
chiatric units at Beth Israel Medical Center (BIMC) in New
York City, from the Psychiatric Outpatient Service for
Adults (POSA) at BIMC, and from ads in local newspapers
and on the internet website "craigslist.org" http://
newyork.craigslist.org. Inclusion criteria for participation
were: 1) males and females, ages 21 – 55; 2) a history of
panic attacks; 3) a DSM-IV diagnosis of Panic Disorder,
with or without agoraphobia; or Major Depressive Disor-
der with Panic Attacks, single episode, recurrent, or
chronic; [36-39] 4) a Hamilton Anxiety Rating Scale
(HAM-A) score of at least 17; and 5) ability to sign
informed consent. The initial diagnosis was determined
by psychiatric interview conducted by experienced BIMC
staff psychiatrists. Because of the frequent comorbidity of
panic attacks and Major Depressive Disorder, we chose to
include patients diagnosed with Major Depressive Disor-
der [37,38,40-42]. We required patients to be between the
ages of 21 and 55 years old so as to avoid possible con-
founding effects of including adolescent and geriatric
patients. A baseline Ham-A score of at least 17 was
required to exclude patients who were asymptomatic and
would not therefore demonstrate improvement with any
medication. Patients with a current or lifetime history of
any Axis I diagnosis other than Panic disorder or Major
Depressive Disorder with Panic Attacks were excluded.
Participants were also excluded for 1) a history of alcohol
or substance abuse within the 6 months preceding enroll-
ment; 2) use of any antipsychotic medications in the two
months preceding enrollment; 3) a history of changes in
antidepressant or mood stabilizer dosing during the two
months preceding enrollment; 4) use of psychoactive
medications other that risperidone or paroxetine during
the study period; or 5) a history of adverse reaction to
either risperidone or paroxetine. All interested subjects
who met the inclusion and exclusion criteria were entered
into the study after signing an IRB-approved consent
form.
Procedures
Randomization of cases was accomplished using SPSS ver
12.0.1 (SPSS Inc., Chicago Ill.). All subjects were ran-
domly assigned to receive either risperidone or paroxetineBMC Psychiatry 2009, 9:25 http://www.biomedcentral.com/1471-244X/9/25
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on a 1:1 basis. Treatment with risperidone was initiated at
0.25 mg/day. For subjects who did not achieve a remis-
sion of panic symptoms, the dose was increased to 0.5 mg
once a day on day 3. For subjects who experienced morn-
ing sedation, the dose was decreased to 0.125-mg once a
day on day 3. Further dosage adjustment for lack or
response or sedation was accomplished in 0.25 mg incre-
ments as needed. Following conventional treatment
guidelines [43], treatment with paroxetine was initiated at
30-mg/day. For the subjects who did not achieve a remis-
sion of panic symptoms, the dose was increased as
needed. Maximal allowable doses of risperidone and par-
oxetine were 16 mg/day and 60 mg/day, respectively.
Treatment with adjunct psychotropic medications during
the study period was not allowed.
The study period was eight weeks in length, during which
subjects were assessed at 10 different time points: at the
initial interview before receiving any study medication, on
study medication day three, on study medication day
seven, and once a week thereafter for a total of eight
weeks. Subject assessments were conducted by a rater
blinded to medication status. The assessment battery
included both clinician and patient-rated measures.
￿ The 17-item Hamilton Depression Rating Scales
(HAM-D-17) [44-46]. The Ham-D-17 is a clinician-
rated scale, which provides a measurement of symp-
toms of depression. The Ham-D 17 was administered at
all study visits. The total scores were used for analysis.
￿ The Hamilton Anxiety Rating Scale (HAM-A) [47].
The Ham-A is a 14 item clinician-rated measure,
which assesses symptoms of anxiety. The Ham-A was
administered at all study visits. The total scores were
used for analysis.
￿ The Panic Disorder Severity Scale (PDSS) [48]. The
PDSS is a seven-item, clinician-rated assessment of the
symptoms of panic attacks. It was administered at all
study visits. PDSS question 1 (panic attack frequency),
question 2 (panic attack severity), and PDSS total
score were analyzed separately.
￿ The Sheehan Panic Anxiety Scale-Patient (SPAS-P)
[49]. A rating scale completed by patients, comprised
of 35 items which provides a measure of anxiety symp-
toms. It was administered at all study visits. The total
scores were used for analysis.
￿ The Clinical Global Impressions Scale (CGI) [50].
The CGI is a physician administered, single item rating
scale that provides an overall assessment of the
patients' condition. The CGI was administered at the
initial and final study visit.
At the end of study period, participants were given the
option to continue their study medications under the care
of one of the study physicians or another psychiatrist at
POSA. Those wishing to discontinue the study medica-
tions at the end of the study were able to do so under the
supervision of one of the study physicians. Paroxetine was
tapered over a two-week period to avoid SSRI withdrawal.
Risperidone was stopped abruptly as no withdrawal
symptoms have been reported in the literature.
Data Analysis
Assignment to a treatment group was carried out using a
1:1 randomization. Group differences in baseline demo-
graphic data were assessed using Chi-squared analysis
for categorical variables, and t-tests for continuous vari-
ables. Data from each outcome measure was checked
against the normal distribution using the Kolmogorov-
Smirnov test of normality. Data from all outcome meas-
ures approximated a normal distribution, with the
exception of the CGI, and subscores 1 and 2 from the
PDSS. Data normalization for items 1 and 2 of the PDSS
was carried out using the following formula: trans-
formed value = log n (original value + 1). Because the
CGI is rated on a discrete 7 point scale, CGI results were
treated as a categorical variable with seven values, and
the comparison of CGI results between groups was
assessed using Chi-squared analysis. An independent
samples t-test was used to compare group means at base-
line for each continuous outcome measure. Analysis of
the over-time change in clinical measures was assessed
using a general linear model for repeated measures as
implemented in SPSS ver 12.0.1 (SPSS Inc., Chicago Ill.).
All subjects were entered on an intent-to-treat basis, with
last observation carried forward (LOCF) for subjects who
terminated study participation prematurely [51,52].
Subject attrition was analyzed by treatment group mem-
bership using a life table analysis. We then used a
Gehan's Generalized Wilcoxon statistic to test the null
hypothesis that study attrition is equal for all groups
[53].
Results
Subject Characteristics
Fifty-six subjects were enrolled in the study: 40 female,
and 16 male (71 and 29%, respectively). Thirty three sub-
jects were randomized to receive risperidone, and 23
received paroxetine (57% and 43%, respectively). In order
to test whether the observed randomization distribution
deviated significantly from the expected distribution (i.e.
28 subjects in each treatment group), we computed the
binomial sampling calculation. With a sample size of 56,
and a random assortment probability of 0.5, the mean
and SD of the binomial sampling distribution is 28 and
3.74, respectively. The exact binomial calculation (one-
tailed) of the probability of an assortment of 33 or greaterBMC Psychiatry 2009, 9:25 http://www.biomedcentral.com/1471-244X/9/25
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in this sample of 56 is 11.44%. This suggests to us that the
observed subject randomization occurs within a statisti-
cally reasonable frequency.
Subject characteristics are presented in Table 1. The aver-
age age for all subjects was 40.36 ± 12.37 years. Forty three
subjects were diagnosed with Panic Disorder, and thirteen
were diagnosed with major depressive disorder with panic
attacks (76.8% and 23.2%, respectively). The treatment
groups did not differ significantly in age, gender make-up,
or psychiatric diagnosis. The average dose for the risperi-
done group was 0.53 mg. (range 0.125 – 1.0 mg.); for the
paroxetine group, all subjects received a dose of 30 mg.
except one subject who was given a final dose of 40 mg.
Retention
Twenty nine subjects completed all 10 visits in the study
period, and 27 dropped out prematurely (51.8% and
48.2%, respectively). In the risperidone group, 20 subjects
(60.6%) completed all 10 study visits, and 13 subjects
(39.4%) dropped out prematurely. In the paroxetine
group, nine subjects (39.1%) completed all 10 study vis-
its, and 14 subjects (60.9%) dropped out prematurely. By
chi-square analysis, there was no statistical difference
between the proportions of subjects in each group that
did not complete the study. Subject retention over the
course of the study for each group was examined using the
Wilcoxon (Gehan) statistic. For group membership the
statistic value is 1.28, and is not statistically significant
(Figure 1). This indicates that the survival curves over the
course of the study did not differ statistically between the
two treatment groups. Reasons for attrition from the study
were: 1) lost to follow-up/non-compliance (n = 14;
51.9%); 2) intolerable side effects (n = 3; 11.1%); 3) lack
of therapeutic response (n = 3; 11.1%). The reason for
attrition was not collected for seven subjects who did not
complete the study. Reasons for attrition from the study
were examined for each treatment group: the Pearson's
chi-square value is 0.87 and is not significant.
Outcome Measures – Baseline
Initial scores on the CGI, Ham-A, SPAS-p, PDSS total,
PDSS item 1, and PDSS item 2 did not differ across groups
(See Table 2). Baseline scores on the Ham-D were signifi-
cantly greater (more severe symptoms) for the paroxetine
group compared to the risperidone group. Initial scores
on the SPAS-p showed a greater mean (more severe symp-
toms) for the risperidone group, compared to the paroxe-
tine group, and this difference was close to, but did not
attain, statistical significance. See Table 2.
Outcome Measures – CGI
All subjects demonstrated a decrease in CGI scores over
the course of the study, regardless of treatment. There was
no difference in the over-time change in CGI scores
between groups. For all subjects together, there was a sig-
nificant decrease in CGI scores between the first and the
last assessment (Wilcoxon signed rank test Z = 4.15, p <
0.001). Group differences in the over-time change in CGI
scores were calculated by subtracting the last CGI score
Table 1: Demographics
Risperidone Paroxetine Statistics
N3 3 2 3
Gender χ2 = 0.74; n.s.
Males (%) 8 (24) 8 (35)
Females (%) 25 (76) 15 (65)
Diagnosis χ2 = 0.74; n.s.
Panic Disorder (%) 24 (73) 19 (83)
MDD (%) 9 (27) 4 (17)
Age: mean (± SD)1 38.82 (9.74) 42.57 (14.34) t = 1.16; n.s.
Terminated (%)2 13 (39)4 14 (61)4 χ2 = 2.50; n.s.
LTF/Non-compliance (%) 9 (69)5 5 (36)5 χ2 = 0.873; n.s.
Adverse Effects (%) 2 (15)5 1 (11)5
Lack of Response (%) 2 (15)5 1 (11)5
Demographic data for study subjects. Percentages represent within-group proportion
1 Age in years
2 Number of subjects failing to complete the study.
3 Testing the difference between groups for the reason for attrition
4 Percentage of all subjects within treatment group
5 Percentage of terminated subjects within treatment group
n.s. – not statistically significant
LTF – lost to follow-upBMC Psychiatry 2009, 9:25 http://www.biomedcentral.com/1471-244X/9/25
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from the initial CGI score, and comparing the results
across treatment groups. The difference between groups in
the over-time change in CGI scores was not significant (χ2
= 7.45; df = 4; p = 0.114). The change in CGI scores are
graphically represented in Figure 2.
Outcome Measures – PDSS, Ham-A, and Ham-D
For the measures PDSS total score, PDSS item 1, PDSS
item 2, Ham-A, and Ham-D, all subjects, regardless of
treatment group, demonstrated a significant decrease in
outcome scores during the course of the study. By the end
of the study period, there was no statistical difference
between the treatment groups in the total scores. The
omnibus test demonstrated a significant change in total
scores over time but no significant effect of group mem-
bership on the change over time. The tests of the within-
subject contrasts comparing measurements made at each
visit with scores at baseline were all significant at the level
of p < 0.005 or lower, with the exception of the contrast of
visit 1 with visit 2 for PDSS total score, which was signifi-
cant at p = 0.037. This data is presented graphically in
Table 3, and Figures 3 and 4.
Outcome Measures – SPAS-p
There was little change in SPAS-p scores over time, regard-
less of treatment group. Average SPAS-p scores were lower
in the risperidone group compared to the paroxetine
group throughout the course of the study, but this differ-
ence was non-significant. The omnibus test demonstrated
no significant change in SPAS-p scores over time, and no
significant effect of group membership on the change over
time. The change in SPAS-p scores are graphically repre-
sented in Table 3 and Figure 4.
Post Hoc Studies
Based on our observation of treatment group differences
in outcome scores during the initial weeks of the trial, we
performed independent sample t-tests to compare out-
come measures at visits 3 and 4 across treatment groups.
For the Ham-A, the risperidone group had a significant
reduction in the mean visit 3 score (14.31 ± 9.83) com-
pared to the paroxetine group (20.3 ± 9.26), where t =
2.28, and p = 0.026. Additionally, the risperidone group
demonstrated a significant reduction in the mean Ham-A
visit 4 score (13.69 ± 9.63) compared to the paroxetine
group (19.78 ± 8.33) (t = 2.25, p = 0.018). For the Ham-
D measure, the risperidone group again had a lower mean
score at visit 3 compared to the paroxetine group (19.15 ±
11.16 and 25.95 ± 11.72, respectively). This difference
was significant (t = 2.17, p = 0.034). Although the risperi-
done group had a lower mean visit 4 Ham-D score than
the paroxetine group (18.61 ± 11.28 vs. 22.23 ± 11.79),
this difference was not statistically significant (t = 1.15, p
= 0.26). For the PDSS total score, the difference across
treatment groups in mean visit 3 and mean visit 4 scores
were not significant (visit 3: t = 1.10, p = 0.28; visit 4: t =
1.02, p = 0.31). Total PDSS scores for the risperidone and
paroxetine groups, respectively, were 8.61 ± 5.58 and
10.35 ± 5.59 on visit 3 and 8.41 ± 6.0 and 10.13 ± 6.32 on
visit 4. In summary, compared to subjects receiving parox-
etine, subjects receiving risperidone had significantly
reduced symptoms as measured by the Ham-A at visits 3
and 4, and by the Ham-D at visit 3.
Our results show that baseline Ham-D scores were signif-
icantly higher in the paroxetine group than in the risperi-
done group, potentially confounding any treatment
effect. Additionally, we found significant positive correla-
tions of baseline Ham-D scores with both baseline and
outcome measures of anxiety symptoms: the correlation
of baseline Ham-D with baseline Ham-A scores was 0.541
(p < 0.001), with V5 Ham-A scores was 0.439 (p = 0.001),
with V10 Ham-A scores was 0.381 (p = 0.005), with base-
line total PDSS was 0.259 (p = 0.067), with V5 total PDSS
scores was 0.379 (p = 0.006), and with V10 total PDSS
scores is 0.246 (p = 0.076). With this positive correlation
of baseline Ham-D and key outcome measures, covarying
baseline Ham-D scores in the repeated measure analysis
has the mathematical effect similar to covarying the out-
come measure with itself, rendering such an analysis
meaningless. Indeed, when the subjects' baseline Ham-D
scores were entered as covariates in the statistical analysis,
treatment effects for all subjects were reduced in signifi-
cance (see Table 3).
As an alternative, we elected to stratify all subjects by base-
line Ham-D score and redo the repeated measures analysis
for each sub-group. All subjects were divided into high
and low Ham-D groups as determined by their baseline
Ham-D score. Using the median baseline Ham-D score of
26.0 as the cut-off, there were 25 subjects classified as low
Ham-D, and 30 subjects classified as high Ham-D. In sub-
jects receiving risperidone, low and high Ham-D subjects
were 51.5% and 48.52%, respectively; for subjects receiv-
Survival by Group Figure 1
Survival by Group. Subject study attrition by treatment 
group.
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ing paroxetine, low and high Ham-D subjects were 36.4%
and 63.6%, respectively. The proportion of low and high
Ham-D subjects did not differ significantly across treat-
ment groups (χ2 = 1.22; df = 1; p = 0.27). The repeated
measures test for PDSS and Ham-A scores were then
retested on each sub-group (see Table 3). These results are
consistent with the findings of our primary analysis done
for all subjects together.
Discussion
This preliminary study compares the effectiveness of risp-
eridone and paroxetine for the treatment of panic attacks.
We found that both risperidone and paroxetine were
effective in reducing the occurrence and severity of panic
attacks. Additionally, there was no difference in the effi-
cacy of risperidone and paroxetine in ameliorating the
symptoms of anxiety associated with panic disorders, as
evidenced by the improvements over time in the scores of
the Ham-A, Ham-D, PDSS, and CGI. As measured by
retention in the study, treatment with risperidone
appeared to be tolerated as well as paroxetine; there was
no difference in retention between the two treatment
groups. These results suggest that low-dose risperidone is
an effective treatment for panic attacks and anxiety in
individuals with panic attacks.
We have presented evidence that suggests that treatment
with risperidone results in a faster symptomatic relief than
does treatment with paroxetine. Group means of the total
PDSS, panic attack frequency, panic attack severity, and
Ham-A all showed a faster decline in the risperidone
group than in the paroxetine group. However, using a gen-
eral linear model repeated measures test, these differences
did not achieve statistical significance. We suspect this dif-
ference was not demonstrated statistically because our
study was not sufficiently powered. Using less restrictive t-
tests to examine group differences at specific points of
time, we demonstrated a statistically significant decrease
in scores of the Ham-A at visits three and four, and scores
of the Ham-D at visit three, in the risperidone group com-
pared to the paroxetine group. However, no group differ-
ences in PDSS scores were identified at either visit three or
four. Confirmation of a faster treatment response using
either medication may require a study using a larger sam-
ple group.
The observed reduction of anxiety symptoms in this sample
is potentially confounded by the presence of the diagnosis
CGI Scores Over Time Figure 2
CGI Scores Over Time. CGI scores at baseline and at ter-
mination by treatment group, as a percent of baseline score. 
Scores for subjects terminating study treatment prematurely 
were carried forward to V10.
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Table 2: Outcome measures at baseline and at the final 
assessment.
Baseline (V1) Final (V10)
CGI
Risperidone 4.40 (± 0.60) 2.84 (± 1.02)
Paroxetine 3.81 (± 1.33) 2.67 (± 0.71)
Statistics3 χ2 = 7.10, df = 5, n.s
PDSS
Risperidone 13.5 (± 4.42) 7.87 (± 5.87)
Paroxetine 12.38 (± 6.77) 8.35 (± 6.15)
Statistics3 t = 0.715, df = 49, n.s.
PDSS question 11
Risperidone 1.16 (± 0.058) 0.70 (± 0.088)
Paroxetine 0.94 (± 0.072) 0.60 (± 0.11)
Statistics3 t = 1.77, df = 29.47, p = n.s.
PDSS question 22
Risperidone 2.41 (± 0.875) 1.28 (± 1.17)
Paroxetine 2.39 (± 1.27) 1.52 (± 1.12)
Statistics3 t = 0.049, df = 36.55, n.s.
Ham-A
Risperidone 25.09 (± 5.27) 13.75 (± 9.67)
Paroxetine 27.76 (± 7.75) 16.22 (± 9.51)
Statistics3 t = 1.49, df = 51, n.s.
SPAS-p
Risperidone 72.53 (± 27.51) 74.69 (± 24.6)
Paroxetine 87.52 (± 25.46) 84.61 (± 30.12)
Statistics3 t = 2.00, df = 51, p = 0.051
Ham-D
Risperidone 26.19 (± 8.37) 17.52 (± 10.91)
Paroxetine 31.0 (± 8.74) 21.68 (± 11.79)
Statistics3 t = 2.01, df = 51, p = 0.049
Initial and final assessments for all outcome measures.
1 – panic attack frequency
2 – panic attack severity
3 – testing the difference in baseline scores between treatment 
groupsBMC Psychiatry 2009, 9:25 http://www.biomedcentral.com/1471-244X/9/25
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of major depressive disorder in 23% of our subjects. Addi-
tionally, as demonstrated by the post hoc analyses, there
was a positive correlation of Ham-D scores with Ham-A
scores, and to a lesser extent PDSS scores. We therefore can
not know if the anxiolytic effect of risperidone is secondary
to a concomitant reduction in symptoms of depression. We
attempted to examine the effect of baseline depressive
symptomatology on anxiolytic efficacy of the medications
under study by stratifying our subjects into high and low
depression groups and re-testing the change in anxiety
scores. Both the subjects identified as having high depres-
sive symptoms and low depressive symptoms at baseline
demonstrated a similar anti-anxiety response to the two
study medications. We conclude that in our sample of sub-
jects the anxiolytic response to the study medications was
no different in subjects with more depressive symptoms
than in subjects with fewer depressive symptoms.
Previous studies of risperidone in anxiety disorders have
focused on generalized anxiety disorder, obsessive-com-
pulsive disorder, and post-traumatic stress disorder [54].
To the best of our knowledge, this is the first study to
examine the effectiveness of risperidone in treating panic.
Our results in patients with panic attacks are consistent
with previous studies of the effectiveness of risperidone in
other anxiety disorders. Brawman-Mintzer [27] reported
that adjunctive risperidone was more effective than pla-
cebo in subjects suffering with generalized anxiety disor-
der. Adjunctive risperidone was also reported to be
effective in reducing symptoms of post-traumatic stress
disorder as well as scores of the Ham-A and the positive
subscale of the Positive and Negative Syndrome Scales
(PANSS) in patients diagnosed with post-traumatic stress
disorder [32]. Risperidone augmentation has been shown
to be effective in reducing anxiety symptoms in a group of
patients with a variety of anxiety disorders refractory to
adequate treatment with antidepressants and/or benzodi-
azepines [55]. In a study of risperidone monotherapy, ris-
peridone was reported to be more effective than placebo
in reducing anxiety in women diagnosed with PTSD [56].
Our results provide further evidence of the utility of risp-
eridone as an anxiolytic agent. Moreover, our study sug-
gests that this anxiolytic activity is present when
risperidone is used as monotherapy.
Table 3: Repeated Measures Testing
Effect of Time Effect of Treatment on Time
PDSS
All Subjects F (9,40) = 3.71; p = 0.002 F (9, 40) = 1.11; p = 0.10
Low Ham-D group1 F (9,14) = 2.69; p = 0.047 F (9,14) = 2.01; p = 0.12
High Ham-D group2 F (9,16) = 1.98; p = 0.11 F (9,16) = 0.22; p = 0.99
PDSS q1
All Subjects F (8,44) = 4.42; p < 0.001 F (8,44) = 1.41; p = 0.22
Low Ham-D group1 F (8,17) = 2.34; p < 0.067 F (8,17) = 1.85; p = 0.14
High Ham-D group2 F (8,18) = 1.75; p = 0.15 F (8,18) = 0.45; p = 0.87
PDSS q2
All Subjects F (8,44) = 5.16; p < 0.001 F (8,44) = 1.25; p = 0.29
Low Ham-D group1 F (8,18) = 5.19; p < 0.002 F (8,18) = 0.85; p = 0.57
High Ham-D group2 F (9,18) = 2.3; p = 0.064 F (9,18) = 1.36; p = 0.28
Ham-A
All Subjects F (8,43) = 8.81; p < 0.001 F (8,43) = 1.90; p = 0.077
Low Ham-D group1 F (9,15) = 4.24; p = 0.007 F (9,15) = 1.96; p = 0.12
High Ham-D group2 F (9,18) = 5.05; p = 0.002 F (9,18) = 0.75; p = 0.66
SPAS-p
All Subjects F (9,41) = 0.80; p = 0.62 F (9,41) = 0.57; p = 0.82
Ham-D
All Subjects F (9,43) = 4.30; p < 0.001 F (9,43) = 1.17; p = 0.33
Outcome measures tested by a General Linear Model Repeated Measures analysis. Testing was initially done for all subjects together, and then for 
subjects grouped into high or low Ham-D groups based on initial Ham-D scores.
1 – Subset of patients with Ham-D scores < 27
2 – Subset of patients with Ham-D scores ≥ 27BMC Psychiatry 2009, 9:25 http://www.biomedcentral.com/1471-244X/9/25
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It is interesting to note that the one measure that did not
show improvement over the eight week study period was
the SPAS-P. This is a patient-rated measure, the only one
used in this study. All clinician-rated measures demon-
strated improvement over the treatment period. Taken
together, the results from all the outcome measures sug-
gest that clinician/raters perceive improvement when the
patients themselves do not. It is not uncommon in clinical
practice to see evidence of a response to treatment before
the patients' subjective sense of well-being improves. It
may be that with a longer duration of the study period, we
would see improvement in the SPAS-P reflecting the
patients' perception of symptomatic improvement.
Risperidone is an antagonist at both the dopamine D2
receptor family (D2L, D2S, D3, and D4), and the 5-HT2A
receptors [57-59]. Interaction of risperidone with the
dopamine D1 receptor only occurs at very high concentra-
tions. It is the serotonin 5-HT2A and dopamine D2 recep-
tor occupancy that seem to provide the anti-psychotic
effects of risperidone. Studies in lab animals have demon-
strated that induced anxiety increases the release of
dopamine in the prefrontal cortex, amygdala, and other
brain areas [60-63]. Both typical and atypical antipsy-
chotic medications have been shown to block the acquisi-
tion of conditioned fear behavior [64-66]. These data
suggest that risperidone may alleviate anxiety symptoms
through the direct modulation of the dopamine system
[54]. Furthermore, it has been suggested that the anti-anx-
iety effect of selective serotonin reuptake inhibitors
(SSRIs) is due in part to blockade of excitatory 5-HT2A
receptors located on inhibitory γ-aminobutyric acid
PDS Scores Over Time for Risperidone and Paroxetine Treatment Groups Figure 3
PDS Scores Over Time for Risperidone and Paroxetine Treatment Groups. Scores over time for Total PDSS, PDSS 
Item 1, and PDSS Item 2 for two treatment groups, as a percent of baseline score. Scores for subjects terminating study treat-
ment prematurely were carried forward to V10.
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(GABA) interneurons, in turn suppressing the firing of
noradrenergic neurons in the locus ceruleus [67,68].
Indeed, the affinity of risperidone for the 5-HT2A receptor
is greater than its affinity for D2 receptors [54,69]. Thus,
our data suggest that the dual action of risperidone in sup-
pressing both dopaminergic and serotonergic activity may
be beneficial for an anxiolytic effect.
One reason we were interested in studying risperidone as
a treatment for panic attacks is our belief that sympto-
matic relief may occur using very low doses, with a con-
comitant reduction in adverse effects. Our results show
that risperidone has effective anxiolytic properties at doses
far below those used in treating psychosis. The average ris-
peridone dose in our subjects was 0.53 mg/day, and no
patient required treatment with greater than 1.0 mg/day;
a dose less than one-half that typically used for treating
psychosis. Few subjects complained of adverse effects to
either of the medications under study. Two subjects in the
risperidone group and one subject in the paroxetine group
complained of adverse effects. This difference was not sta-
tistically significant, and suggests that the acceptance of
risperidone in our sample is comparable to that of parox-
etine. Our study of subject attrition during the course of
Ham-A, Ham-D, and SPASp Scores Over Time for risperidone and Paroxetine Treatment Groups Figure 4
Ham-A, Ham-D, and SPASp Scores Over Time for risperidone and Paroxetine Treatment Groups. Scores over 
time for Total Ham-A, Total Ham-D, and Total SPASp for two treatment groups. Scores for subjects terminating study treat-
ment prematurely were carried forward to V10.
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the study showed no difference between the two treat-
ment groups in attrition, and gives further evidence that
subjects' tolerability to risperidone did not differ from
that of paroxetine.
The results of this study should be considered in conjunc-
tion with its limitations. Our study was limited by the
short 8 week follow-up period that does not provide for
data on the long-term efficacy and safety of the use of ris-
peridone in patients with panic attacks. Additionally, our
report is limited by the loss of data because of subject attri-
tion, which in this study amounted to 48% of the total
sample. As such, our study perhaps better mirrors the
experience of clinicians in an office practice where
patients frequently fail to return for appointments
[70,71]. Baseline Ham-D scores differed between treat-
ment groups; though we have tried with our post-hoc test-
ing to elucidate the possible significance of this difference,
the overall significance is unknown. The initiation of
medications was titrated for Risperidone, but no titration
was used for the Paroxetine group, possibly confounding
treatment and survival data. We did not use a standard-
ized diagnostic instrument verify the subjects' diagnoses.
Because we studied patients with both MDD and PD, we
cannot make firm conclusions about the effectiveness of
Risperidone as a treatment for PD. Additionally, it is pos-
sible that subjects with MDD and PD will have different
responses to the study medications, and our results are
confounded by these as yet unreported differences. Lastly,
we did not record tobacco use among our sample, and
given the reported link between cigarette smoking and
panic attacks [72], our results may be confounded by
smoking in unknown ways.
Conclusion
The strengths of our study are the prospective, rand-
omized design, the use of risperidone as monotherapy,
the use of an effective comparator medication, and the
multiple measures of anxiety symptoms employed. In it
we have shown that low-dose risperidone provides effec-
tive relief of panic attacks and concomitant symptoms of
anxiety. Risperidone appears to be well-tolerated. In addi-
tion, it is possible that low-dose risperidone results in
faster symptomatic relief than paroxetine. Further studies
involving larger groups are necessary to confirm these
results.
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